Clinical trialNCT01482767CompletedPhase 3Interventional

Evaluating the Effectiveness of Boceprevir, Pegylated-Interferon Alfa 2b and Ribavirin in Treating Hepatitis C Virus (HCV) Infection in Adults With HIV and HCV Infection

SponsorNational Institute of Allergy and Infectious Diseases (NIAID)Enrollment262HIV InfectionsHepatitis C

View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

Hepatitis C virus (HCV) infection is a leading cause of death and illness in people with HIV-1. At the time the study was designed, the standard treatment for people with HIV-1 and HCV coinfection included two drugs: pegylated-interferon alfa 2b (PEG-IFN) and ribavirin (RBV). The purpose of this study was to evaluate the effectiveness of giving boceprevir (BOC) together with standard treatment in treating HCV infection in people with HIV-1 and HCV coinfection.

clinicaltrials.gov ↗

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

Adeel A Butt, MD, MS
University of Pittsburgh
Study ChairKOL profile →
clinicaltrials.gov ↗
Kenneth E Sherman, MD, PhD
University of Cincinnati CRS
Study Chair
clinicaltrials.gov ↗

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

43 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

Puerto Rico

Puerto Rico Aids Clinical Trials Unit Crs
San Juan, Puerto Rico

United States

Alabama Crs
Birmingham, Alabama, United States
Ucla Care Center Crs
Los Angeles, California, United States
University of Southern California Crs
Los Angeles, California, United States
Stanford Aids Clinical Trials Unit Crs
Palo Alto, California, United States
Ucsd Antiviral Research Center Crs
San Diego, California, United States
Ucsf Hiv/aids Crs
San Francisco, California, United States
Harbor-Ucla Crs
Torrance, California, United States
University of Colorado Hospital Crs
Aurora, Colorado, United States
Denver Public Health Crs
Denver, Colorado, United States
Georgetown University Crs (gu Crs)
Washington D.C., District of Columbia, United States
the Ponce de Leon Center Crs
Atlanta, Georgia, United States
Northwestern University Crs
Chicago, Illinois, United States
Rush University Crs
Chicago, Illinois, United States
Ihv Baltimore Treatment Crs
Baltimore, Maryland, United States
Johns Hopkins University Crs
Baltimore, Maryland, United States
Bmc Actg Crs
Boston, Massachusetts, United States
Brigham and Women'S Hospital Therapeutics Clinical Research Site (bwh Tcrs) Crs
Boston, Massachusetts, United States
Massachusetts General Hospital Crs (mgh Crs)
Boston, Massachusetts, United States
Henry Ford Hosp. Crs
Detroit, Michigan, United States
Wayne State Univ. Crs
Detroit, Michigan, United States
Washington University Therapeutics (wt) Crs
St Louis, Missouri, United States
Cooper Univ. Hosp. Crs
Camden, New Jersey, United States
New Jersey Medical School Clinical Research Center Crs
Newark, New Jersey, United States
Columbia P&s Crs
New York, New York, United States
Weill Cornell Chelsea Crs
New York, New York, United States
Weill Cornell Uptown Crs
New York, New York, United States
University of Rochester Adult Hiv Therapeutic Strategies Network Crs
Rochester, New York, United States
Bronx-Lebanon Hosp. Ctr. Crs
The Bronx, New York, United States
Chapel Hill Crs
Chapel Hill, North Carolina, United States
Duke Univ. Med. Ctr. Adult Crs
Durham, North Carolina, United States
Cincinnati Clinical Research Site
Cincinnati, Ohio, United States
Case Clinical Research Site
Cleveland, Ohio, United States
Metrohealth Crs
Cleveland, Ohio, United States
Ohio State University Crs
Columbus, Ohio, United States
Penn Therapeutics, Crs
Philadelphia, Pennsylvania, United States
University of Pittsburgh Crs
Pittsburgh, Pennsylvania, United States
the Miriam Hospital Clinical Research Site (tmh Crs) Crs
Providence, Rhode Island, United States
Vanderbilt Therapeutics (vt) Crs
Nashville, Tennessee, United States
Trinity Health and Wellness Center Crs
Dallas, Texas, United States

3 more sites on the registry record.ClinicalTrials.gov ↗

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

BoceprevirPegylated-Interferon Alfa 2bRibavirin →

Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start: 30 Apr 2012
Primary completion: 30 Apr 2015
Completion: 30 Apr 2015
Last update posted: 4 Nov 2021
Registered enrollment: 262
Registry id: NCT01482767

clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.